Quarterly Updates5 Feb 2026, 07:42 pm
Anthem Biosciences Reports Q3FY26 and 9MFY26 Financial Results with 41.5% EBITDA Margins
AI Summary
Anthem Biosciences Limited, an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization, announced unaudited results for the third quarter and period ended December 31, 2025. The company reported consolidated revenue from operations of 4,232 Mn for Q3FY26 and 15,134 Mn for 9MFY26 with EBITDA margins of 41.8% and 41.5% respectively. The CRDMO business contributed significantly to the revenue with 33,332 Mn in Q3FY26 and 12,599 Mn in 9MFY26. The new labour codes in India impacted the exceptional items and profit before tax for both Q3FY26 and 9MFY26.
Key Highlights
- Consolidated revenue from operations for Q3FY26 stood at 4,232 Mn with a YoY growth of 11.2% and QoQ growth of 15.0%.
- CRDMO business delivered revenues of 33,332 Mn in Q3FY26 with a YoY growth of 13.1%.
- Specialty Ingredients delivered revenues of 3,899 Mn in Q3FY26 with a QoQ growth of 2.5%.
- EBITDA for Q3FY26 was 31,907 Mn at 41.8% EBITDA margins.
- PAT for Q3FY26 was 928 Mn with PAT margins at 20.3%.